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E-mail address: votrubam@cardiff.ac.uk (M. VotruDominant optic atrophy (DOA) is the most common inherited optic neuropathy affecting one in every
12,000 people. It presents with bilateral visual loss, central visual ﬁelds defects, colour vision disturbance
and optic disc pallor. OPA1 has been identiﬁed as the responsible gene and its locus mapped to chromo-
some 3q28-q29. Mutations in this gene are responsible for the clinical phenotype in over 70% of patients
with DOA. Histopathological studies in tissues from patients reveal loss of retinal ganglion cells but the
paucity of viable human tissue has raised the importance of an animal model to study the pathophysiol-
ogy of the disease. In the last decade considerable work has gone into the generation of animal, most
notably mouse, models of Opa1 DOA. Two murine models of DOA have been published, designated
B6;C3-Opa1Q285STOP and B6;C3-Opa1329-355del and they provide valuable insights with respect to neuro-
logical and visual phenotyping, mitochondrial dysfunction, optic nerve and axonal changes, retinal gan-
glion cell depletion and dendritic atrophy. Here we summarise the current state of knowledge of the
mechanisms of disease based on data from these models of Opa1 DOA.
 2010 Elsevier Ltd. All rights reserved.1. Introduction
Mitochondria are dynamic organelles with an essential bioener-
getic function. They continually undergo fusion and ﬁssion, in a
process that is held in equilibrium by various mitochondrial shap-
ing proteins, for ﬁssion; Drp1 and Fis1 (Frank et al., 2001; Lackner
& Nunnari, 2009; Liesa, Palacin, & Zorzano, 2009; Yu, Fox, Burwell,
& Yoon, 2005) and for fusion; the mitofusins (Mfn1 and Mfn2) and
Opa1 (Chen & Chan, 2006; Chen et al., 2003; de Brito & Scorrano,
2009; Song, Ghochani, McCaffery, Frey, & Chan, 2009). Mutations
in OPA1 result in the disease dominant optic atrophy (DOA), which
is characterised by a mild to moderate progressive loss of visual
acuity, central visual ﬁeld defects, colour vision defects and tempo-
ral optic disc pallor. Although the importance of Opa1 protein in
controlling mitochondrial fusion is well known the mechanisms
by which OPA1 mutations cause DOA have yet to be elucidated.
1.1. OPA1 and dominant optic atrophy
Mutations in OPA1 lead to DOA, (Alexander et al., 2000; Delet-
tre, Lenaers, Pelloquin, Belenguer, & Hamel, 2002) the most com-
mon optic neuropathy, with an estimated prevalence of 1:12,000
(Carelli, Ross-Cisneros, & Sadun, 2002) rising to 1:10,000 in certainll rights reserved.
and Vision Sciences, Cardiff
ba).populations (Delettre et al., 2002). DOA typically presents in the
ﬁrst decade of life as bilateral visual loss with pallor of the optic
disc, centrocecal visual ﬁeld scotoma and tritanopia (Delettre
et al., 2002; Votruba, Moore, & Bhattacharya, 1998). Visual loss
may be slowly progressive. There is considerable intra- and inter-
familial variability in severity of visual loss ranging from legally
blind to asymptomatic carriers. Some pedigrees have associated
clinical features such as ptosis, myopathy and progressive external
ophthalmoplegia. Histological assessment from donor eyes shows
thinning of the retinal ganglion cell layer suggesting degeneration
of retinal ganglion cells (RGCs). Demyelination has been observed
in the optic nerve, chiasm and tract (Kjer, Jensen, & Klinken,
1983; Milea et al., 2010). The shape of the optic nerve has been re-
ported to be characteristic (Fournier, Damji, Epstein, & Pollock,
2001; Votruba, Thiselton, & Bhattacharya, 2003) and the size of
the optic nerve head is reduced (Barboni et al., 2010).
Over 200 different OPA1 mutations have been reported to date
(Ferré, Amati-Bonneau, Tourmen, Malthiery, & Reynier, 2005; Oli-
chon et al., 2006). Isolated mutations in the OPA1 gene have also
been shown to cause a ‘DOA plus syndrome’, in which optic
atrophy is accompanied by sensorineural deafness, ataxia, axonal
sensory-motor polyneuropathy, chronic progressive external
ophthalmoplegia and mitochondrial myopathy with cytochrome
c oxidase negative and Ragged Red Fibres (Amati-Bonneau et al.,
2009; Huang, Santarelli, & Starr, 2009; Milone, Younge, Wang,
Zhang, & Wong, 2009; Yu-Wai-Man et al., 2010). Remarkably, it
has recently emerged that, in rare cases, OPA1 mutations can be
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absence of any detectable optic atrophy (Milone et al., 2009).
1.2. The Opa1 protein
The OPA1 gene codes for the protein OPA1, a dynamin-like
mitochondrial related guanosine triphosphatase (GTPase) and a
100 K member of the GTPase superfamily (Hinshaw & Schmid,
1995). OPA1 is homologous with the yeast (Saccharomyces cerevi-
sae) gene Mgm1 (Olichon et al., 2002) and is located primarily on
the mitochondrial inner membrane. Mgm1/Opa1 has multiple
functions, playing a central role in the maintenance of mitochon-
drial morphology and mitochondrial networks through its effects
on endocytosis, vesicular trafﬁc and coated vesicle formation (Hin-
shaw & Schmid, 1995). It also inﬂuences mitochondrial motility
(including mitochondrial ﬁssion and fusion) to ensure an appropri-
ate distribution of mitochondria and adequate supplies of ATP
within the cytosol. OPA1 is thought to play a protective role as
an anti-apoptotic GTPase by limiting the detrimental impact of
apoptotic stimuli (Davies et al., 2007). The OPA1 protein is ex-
pressed ubiquitously throughout the body with high levels in the
retina, brain (Aijaz, Erskine, Jeffery, Bhattacharya, & Votruba,
2004; Misaka, Miyashita, & Kubo, 2002) liver and heart. Given
the critical importance of OPA1 to so many cellular activities it is
interesting that OPA1 mutations manifest primarily as DOA (Da-
vies & Votruba, 2006).
1.3. Mouse models of dominant optic atrophy
Ocular and CNS tissue from patients with DOA is scarce and the
published histology of DOA has come from a very small number of
elderly patients with severe disease (Johnston, Gaster, Smith, & Tri-
pathi, 1979; Kjer et al., 1983). This limitation has created a pressing
need for an animal model of DOA. Such a model must combine the
genetic and clinical characteristics of DOA in animals that are suit-
able for genetic analysis. Mice are widely used as genetic disease
models due to the relative ease of genetic manipulation and high
homology to thehumangenome. Themurine retina shows relatively
good homology to the human retina rendering the mouse suitable
for modelling a wide range of human visual diseases with a genetic
basis (Smith, John, Nishina, & Sundberg, 2002). However, there is a
range of anatomical limitations, and it should be recognised that
although the murine eye is a good model for human eye disease it
is by no means perfect. Despite this, much has been learnt from
mouse models of human genetic eye disease. In the last 5 years
twomousemodels of Opa1DOA (based onOPA1haploinsufﬁciency)
have been published: the B6;C3-Opa1Q285STOP Opa1 mutant mouse
(Davies et al., 2007) and the B6;C3-Opa1329-355del Opa1 mutant
mouse (Alavi et al., 2007). Both display a broad correlation with
thehumanDOAphenotype. (The twomodels are compared and con-
trasted in Table 1.)2. Mouse models of dominant optic atrophy
2.1. Generation of the B6;C3-Opa1Q285STOP and B6;C3-Opa1329-355del
Opa1 mutant mice
Both the B6;C3-Opa1Q285STOP mutant mouse (Davies et al., 2007)
and the B6;C3-Opa1329-355del mutant mouse (Alavi et al., 2007)
were generated after screening an ENU-mutagenized DNA library
of mouse DNA (Ingenium, Martinsried, Germany) for mutants with
sequence changes in Opa1.
The B6;C3-Opa1Q285STOP Opa1 mutant mouse was generated by
screening an ENU-mutagenized DNA archive from C3HeB/FeJ
males for point mutations in Opa1 exons 1, 8, 9, 10, 12 and 28,selecting a heterozygous nonsense mutation in exon 8, which
codes for a C–T transition at 1051 bp (Q285STOP). This mutation
causes protein truncation at the beginning of the dynamin GTPase,
close to the location of a number of human disease mutations
(c.868C>T (R290W) and c.869G>T (R290Q) (Ferré et al., 2005)).
The Opa1 mutant mouse line (B6;C3-Opa1Q285STOP) was produced
through in vitro fertilization with mutant sperm and C57Bl/6 J fe-
males to produce a heterozygous, Opa1±, mouse. The founder
(F1) generation was then systematically outcrossed to C57Bl/6 J
up to at least G4. The pdeb (RD1 mutation), carried by the C3H line,
was excluded by systematic genotyping and breeding. Heterozy-
gous Opa1± mice were intercrossed to generate generation cohorts.
The B6;C3-Opa1329-355del Opa1 mutant mouse was also gener-
ated by screening an ENU-mutagenized DNA library of mouse
DNA and this time identifying a splice site mutation in murine
Opa1 intron 10: c.1065+5G? A. Using a purebred C3HeB/FeJ out-
cross on C57Bl/6 a mouse model for DOA carrying this splice site
mutation in the Opa1 gene was created. The mutation is close to
three reported human mutations (c.1065+2T>C, c1065+2T>G and
c.1065+3A>C (Ferré et al., 2005)) and results in skipping of exon
10 in the OPA1 gene causing an in-frame deletion of 27 amino acid
residues in the dynamin GTPase domain.
Both models show 50% reduction in Opa1 transcript in retinal
tissue and a 50% reduction in Opa1 protein across a range of tis-
sues, suggesting that haploinsufﬁciency underlies the pathophysi-
ological mechanism. Both the B6;C3-Opa1Q285STOP and B6;C3-
Opa1329-355del mutant mouse are embryonic lethal when homozy-
gous; at <E13.5 in the B6;C3-Opa1Q285STOP mutant mouse (Davies
et al., 2007) and ca. E8.5 (between E3.5 and E12) in the B6;C3-
Opa1329-355del mutant mouse (Alavi et al., 2007).
2.2. Visual, neurological and neuromuscular abnormalities
Visual function in the B6;C3-Opa1Q285STOP mutant mouse has
been assessed with a rotating optokinetic drum (OKN) using high
(2, corresponding to 0.25 cycles/degree) to low (4 and 8, 0.125
and 0.0625 cycles/degree) resolution gratings. Two studies (Davies
et al., 2007; Yu-Wai-Man et al., 2009) have looked at visual func-
tion at 6, 12, 13 and 18 month old mice. Signiﬁcantly decreased
mean tracking frequencies from 12 months in Opa1± mice were de-
tected at high and low spatial frequencies. Furthermore, reduced
detection of the low resolution gratings was documented from
18 months onwards in Opa1± mice.
Given the ubiquitous expression of Opa1 (Alexander et al., 2000)
an Opa1 deﬁciencymay be expected to adversely affect other organ
systems, especially those with high levels of mitochondria and high
metabolic demands. Detailed (non ocular) phenotyping of the
B6;C3-Opa1Q285STOP mouse model by SHIRPA neurological testing
has revealed subtle systemic neurological and neuromuscular
abnormalities (Davies et al., 2007), such as decreased locomotor
activity.
There are several reported neurological and metabolic abnor-
malities in the B6;C3-Opa1329-355del mutant mouse phenotype (Ala-
vi et al., 2009). SHIRPA testing showed that over a half of the Opa1
mutant mice had an abnormal clutching reﬂex with a third (11
males and 2 females) suffering a tremor by 22 months of age.
Opa1 mutant mice also performed signiﬁcantly worse than con-
trols on the Rotarod; a rotating rod used to test the physical perfor-
mance of rodents. Although Opa1 mutant mice maintained a
normal food intake they were signiﬁcantly lighter than controls
regardless of sex. Post-mortem examination revealed signiﬁcantly
less body fat than controls though the muscle ﬁbre morphology
was unaffected. The extra-ocular phenotype reported in the
B6;C3-Opa1329-355del mutant mouse has recently been supported
by ﬁndings on Rotarod in the B6;C3-Opa1Q285STOP. This also applies
to the tendency for B6;C3-Opa1Q285STOP mutants to have lower
Table 1
A comparison of the B6;C3-Opa1Q285STOP and B6;C3-Opa1329-355del Opa1 mouse models.
Clinical phenotype OPA1DOA B6;C3-Opa1Q285STOP B6:C3-Opa1329-355del
Mutation All exons except exon 4, 4b and 5. Exon 8 Intron 10
Substitutions, deletions and insertions
(Ferré et al., 2005)
Nonsense mutation Splice site mutation
Evidences for haploinsufﬁciency
(Pesch et al., 2001)
At DNA level: c. 1051C > T At DNA Level: c. 1065+5G>A
At protein level: p.Q285 At protein level: p.329-355del
50% reduction in protein levels
(Davies et al., 2007)
50% reduction in protein levels
(Alavi et al., 2007)
Mitochondria Loss of mtDNA in ‘plus’ mutations
(Amati-Bonneau et al., 2009)
mtDNA copy number: no signiﬁcant
difference compared to wt counterparts
mtDNA copy number: no signiﬁcant
difference compared to wt counterparts
Morphology fragmentation in patient
ﬁbroblasts (Lenaers et al., 2009;
Carelli et al., 2002)
Morphology: powdered appearance Morphology: disorganised cristae
(Alavi et al., 2007)
Increased mitophagy
(Davies et al., 2007)
Mouse N/A Strain: C3H:C57Bl/6 J Strain: C3H:C57Bl/6
Generation: >G4 (Davies et al., 2007;
Yu-Wai-Man et al., 2009)
Generation: inter-crosses of F1
(Alavi et al., 2007)
Homozygous mutant Presumed embryonic lethal Embryonic lethality <E13.5
(Davies et al., 2007)
Embryonic lethality ca. E8.5
(Alavi et al., 2007)
Phenotype
Age observed (months,  = most signiﬁcant)
Visual function and
electrophysiology
Acuity range from 6/6 to registered blind
(Kjer et al., 1996)
Decreased visual function assessed
by OKN (Davies et al., 2007)
6, 12 Decrease in VEP amplitude 20–24
Optic atrophy with disc pallor
(Votruba et al., 1998)
No signiﬁcant change in
ERG even in aged mice
(Heiduschka et al., 2010)
2, 9, 24
VEP decreased amplitude ± increased
latency, PERG P50:N95 ratio decreased
(Holder et al., 1998)
‘Plus ’phenotype Sensorineural deafness, ataxia, axonal
sensory-motor polyneuropathy, chronic
progressive external opthalmoplegia and
mitochondrial myopathy with cytochrome c
oxidase negative and ragged red ﬁbres
(Yu-Wai-Man et al., 2009)
Increased transfer arousal
Longer freezing periods 6 for all Abnormal clutching reﬂex 22
Decreased locomotor activity
(Davies et al., 2007)
Tremor 22
No COX-SDH ragged red ﬁbres











red ﬁbres (Alavi et al., 2009)
RGC population and
morphology
RGC loss (Kjer et al., 1983;
Johnston et al., 1979)








(Heiduschka et al., 2009)
13, 17, 20
Dendritic atrophy with age
limited to sublamina b
Williams et al., 2010
10–15, >20
Optic nerve Demyelination Demyelination 24 Demyelination 8
Ascending optic neuropathy
(Kjer et al., 1983; Johnston et al.,1979)
Myelin clumping 18; 24 Disorganisation For all
Watery degeneration 9, 24 Swollen and distorted axons
Dark degeneration 9, 24 Complete loss of large axons
No axon loss (Davies et al., 2007;
White et al., 2009)
6, 9, 24 Signiﬁcant loss of small
axons (Alavi et al., 2007)
P.A. Williams et al. / Vision Research 51 (2011) 229–234 231body weight (Taylor, Davies, Powell, Davies, & Votruba, 2010). Of
signiﬁcance is the fact that neither model displayed hearing loss.
Both models have been aged up to 24+ months but no robust
quantitative data on life expectancy has been published.
2.3. Retinal ganglion cell populations
Both models show normal clinical fundal appearances on di-
lated ophthalmoscopy. Pattern electroretinogram (PERG) data from
patients with DOA show a consistent reduction in the retinal gan-
glion cell speciﬁc P50:N95 ratio (Holder, 2004; Holder et al., 1998).
Visually evoked potential (VEP) data in DOA patients show variablereduction in amplitude, suggestive of RGC loss, with occasional de-
lay documented in some patients, consistent with axon dysfunc-
tion/damage.
Electroretinography (ERG) in the B6;C3-Opa1329-355del mutant
mouse at 2 and 9 months was normal (Alavi et al., 2007). Reduc-
tions in the ERG could not be detected at 24 months of age when
the disease might be regarded as ‘end-stage’ (Heiduschka et al.,
2010). (Slight reductions were seen in the scotopic a-wave (photo-
receptors) and b-wave (rod bipolar cells (Pinto, Invergo, Shimom-
ura, Takahashi, & Troy, 2007)) and photopic b-wave amplitudes
in the Opa1 mice, but these changes did not reach statistical signif-
icance.) However, assessment of the visual pathway by visual
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cant reduction in the amplitude of scotopic VEPs in Opa1 mice and
a non-signiﬁcant reduction in the amplitude of photopic VEPs, but
in neither case was the VEP delayed. This was interpreted as a loss
of RGCs, which could be conﬁrmed by retrograde labelling.
Retrograde labelling from both superior colliculi using hydroxy-
stilbamidine and by Haematoxylin and Eosin staining was under-
taken to quantify any changes in RGC populations (Alavi et al.,
2007). RGC counts were unchanged in 2 and 4 month old Opa1mu-
tant mice but showed a slight reduction by 13 months. These
changes were ﬁrst seen at 9 months, appearing ﬁrst in the periph-
eral and mid peripheral retina. By 23 months Opa1 mutant mice
showed a marked reduction in RGC layer counts which was con-
ﬁrmed by retrograde RGC labelling. RGCs were reported to be
phagocytosed by retinal microglia (Heiduschka et al., 2010). Histol-
ogy of the retina conﬁrms that there is no abnormality in the pho-
toreceptor or other retinal layers.
Conversely, histological examination of B6;C3-Opa1Q285STOP
mutant mouse retinas by Haematoxylin and Eosin, Hoechst
33258 staining and TUNEL staining reveals no signiﬁcant cell loss
in the retinal ganglion cell layer or death across all age groups,
even at 24 months of age (Davies et al., 2007; Williams, Morgan,
& Votruba, 2010). Retinal architecture and morphology is normal
on histology with no defect in photoreceptors, however, there
was a signiﬁcant increase in the number of autophagosomes in
the RGCs in the retina and surrounding the axons in the 24 month
old Opa1± mice (White et al., 2009) compared to age matched wild
type littermate controls. Since Opa1 is downregulated by ca. 50%, it
is hypothesised that there is a reduction in mitochondrial mem-
brane potential forming dysfunctional depolarized mitochondria,
which must be eliminated by autophagosomes, or recovered by
mitochondria fusion. Since mitochondrial fusion is impaired in this
mouse model of DOA, autophagy of mitochondria (mitophagy) is a
likely outcome. These data suggest that RGC dysfunction rather
than signiﬁcant RGC loss is the early driver for visual dysfunction
in this mouse model.
2.4. Changes in retinal ganglion cell morphology
Speciﬁc changes in RGC morphology have been recorded in the
B6;C3-Opa1Q285STOP mutant mouse. In the absence of signiﬁcant
levels of RGC loss Williams et al. (2010) sought an anatomical basis
for the evident retinal ganglion cell dysfunction and pathological
changes visible in the optic nerve by analysing the connections be-
tween the retinal ganglion cells and the outer retinal layer. The
dendritic morphology of retinal ganglion cells was quantiﬁed at
different ages (4–23 months) using DiOlistic labelling of the retinal
ganglion cell layer (Gan, Grutzendler, Wong, Wong, & Lichtman,
2000; Pignatelli & Strettoi, 2004). Quantitative analysis of dendrite
length, tree area and complexity indicated atrophic changes that
increased with age and were more marked in Opa1± mice. Interest-
ingly, these changes were localised to sublamina b (ON layer) of
the inner plexiform layer, with dendrites synapsing in the outer
OFF layer relatively unaffected. These observations suggest a selec-
tive effect of the mutation on ON-centre compared with OFF-cen-
tre cells. A possible pathophysiological basis for this selectivity
may rest on the different energy demands of ON- and OFF- centre
RGCs and on the different neurotransmitter requirements of these
pathways (Marc, 2008; Xu & Tian, 2007). It is important to note,
that changes in the architecture of the dendritic trees were seen
as early as 10 months and preceded optic nerve defects and vision
loss in this model. The present data suggest that in the B6;C3-
Opa1Q285STOP model vision loss results from RGC dysfunction and
axon and optic nerve abnormalities (Davies et al., 2007; Williams
et al., 2010) rather than ascending RGC death as seen in the
B6;C3-Opa1329-355del mutant mouse model.2.5. Optic nerve pathology
Although optic nerve pallor is a cardinal feature of human DOA,
clinical optic atrophy is hard to categorise in the mouse eye and it
has not been a robust phenotypic marker in either model. In the
B6;C3-Opa1Q285STOP mouse model transmission electron micro-
scopic analyses have indicated little change relative to controls in
the optic nerves of 6 month old Opa1± mice. However, from
9 months to 18 months there were signiﬁcant abnormalities in
the optic nerve fascicles and myelin bundles, which appeared as
large abnormal whirls of myelin as well as the appearance of
noticeable demyelination (Davies et al., 2007) associated with sig-
niﬁcant intra-axonal changes (White et al., 2009). From 9 months
of age these were evident as early signs of watery and dark axonal
degeneration in the Opa1± mice, and reached statistical signiﬁ-
cance by 24 months, by which time axons counts were signiﬁ-
cantly reduced. Since axon loss was evident in both the
24 month Opa1± mice and age matched wild-type controls, it is
likely that the changes reﬂected age related axon loss and not just
the effects of Opa1 deﬁciency.
Similar electronmicroscopic analysis on the B6;C3-Opa1329-355del
mutant mouse (Alavi et al., 2007) has shown a more severe pheno-
type to that of the B6;C3-Opa1Q285STOP mutant mouse showing a
complete loss of large axons and a signiﬁcant loss of small axons
by 8 months of age indicative of RGC degeneration. Optic nerve ax-
ons were swollen and distorted with associated demyelination and
the presence of membranous whorls. The neuroﬁbrillary and colla-
gen contents were both reduced in the optic nerve.
2.6. Clinical relevance of the B6;C3-Opa1Q285STOP and B6;C3-
Opa1329-355del mouse models
The B6;C3-Opa1Q285STOP mouse model is a useful resource for
the study of DOA disease mechanisms since it shows late onset
and subtle changes in RGCs and optic nerve which are associated
with slow progression of the disease. The precise mechanisms link-
ing defects in mitochondrial fusion to visual dysfunction remain
unknown. The B6;C3-Opa1Q285STOP model shows evidence of mito-
chondrial dysfunction with Opa1± mouse muscle ﬁbroblast culture
displaying punctuated and dispersed mitochondria, giving an
abnormal ‘powdered’ appearance (Davies et al., 2007). Apoptosis
of RGCs has been proposed as a pathophysiological mechanism in
DOA, but cell counts and TUNEL labelling in this mouse model
show that visual dysfunction must exist prior to widespread RGC
loss. Thus, this model supports dysfunction of RGCs as an early
stage in DOA pathophysiology. From the data presented it appears
that dendritic pruning of RGCs precedes visual deﬁcit as well as
changes in RGC axons and the optic nerve giving a potential time-
scale for the progression of the disease. The B6;C3-Opa1Q285STOP
mutant mouse harbours no mtDNA deletions associated with the
DOA ‘plus’ phenotype in patients yet there are subtle extra-ocular
neurological abnormalities present suggesting that even those
OPA1 mutations not associated with mtDNA loss in patients can
be associated with neuromuscular defects. This highlights the
importance of conducting full neurological assessments in all
DOA patients (Aijaz et al., 2004; Amati-Bonneau et al., 2009; Yu-
Wai-Man et al., 2009).
The B6;C3-Opa1329-355del mutant mouse provides a good model
of DOA since it retains the key clinical features documented in pa-
tients with similar mutation in OPA1 close to intron 10 c.1065
(c.1065+2T>C, c1065+2T>G and c.1065+3A>C (Ferré et al., 2005;
Pesch et al., 2001; Puomila et al., 2005)). The B6;C3-Opa1329-355del
mouse model of DOA displays no mtDNA deletions (Alavi et al.,
2009). Changes in the optic nerve, RGC populations and abnormal
mitochondria (Alavi et al., 2007) are all present and these follow
clinical observations in patients with DOA. The Opa1 mutant
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loss, a ﬁnding supported by retrograde labelling of RGCs.
The evidence for retinal ganglion cell loss as the only mecha-
nism of disease in clinical DOA is partly based on histological data
conducted over 30 years ago on a small cohort of two very elderly
patients with severe visual loss/‘end-stage’ disease (Johnston et al.,
1979; Kjer et al., 1983). This histology shows retinal thinning and
widespread retinal ganglion cell loss. Recent OCT data (Milea
et al., 2010) conﬁrm the retinal nerve ﬁbre layer thinning. Based
on this data widespread retinal ganglion cell loss in DOA must be
a relevant mechanism, but it may not be the earliest change and
not necessarily even the only one (see Table 1).
VEP data from patients, with reduced amplitude, supports reti-
nal ganglion cell loss; however, some patients’ VEP readings show
an increased VEP latency (Holder et al., 1998) indicative of retinal
ganglion cell dysfunction, in association with cell loss. With over
200 mutations recorded (Ferré et al., 2005) and electrophysiology
available for only a proportion of these, it may be possible that ret-
inal ganglion cell dysfunction precedes loss as the driver for visual
dysfunction, and this effect may be mutation speciﬁc. Unfortu-
nately, due to the constraints of human retinal phenotyping in pa-
tients with early disease it may prove difﬁcult to explore this
hypothesis fully.
Drawing from murine models of other neurodegenerative dis-
eases, such as Alzheimer’s (AD) and Parkinson’s (PD) disease, there
is evidence of both dendritic atrophy (AD) (Grutzendler, Helmin,
Tsai, & Gan, 2007) and widespread neural cell loss (PD) (Beal,
2001) as drivers for the disease and as the major mouse phenotype.
Mitochondrial fusion and ﬁssion are essential for proper dendritic
morphology and we see rapid dendritic remodelling in terms of
dendritic spine morphology when the fusion/ﬁssion balance is dis-
turbed (Li, Okamoto, Hayashi, & Sheng, 2004). Retinal ganglion
cells do not possess dendritic spines but there is evidence for den-
dritic remodelling over a longer time frame (Marc, Jones, Watt, &
Strettoi, 2003). It is feasible that this process is happening in a sub-
set of DOA patients as an early disease marker (as in the B6;C3-
Opa1Q285STOP mouse) and that widespread retinal ganglion cell loss
(as in the B6;C3-Opa1329-355del mouse) occurs prior to gross visual
dysfunction in that same way that there is an 70% neural loss in the
substantia nigra in PD patients before the disease is clinically
apparent.3. Conclusions
Here we compare two models, both showing a clinical pheno-
type compatible with DOA as well as some traits present in the
DOA plus phenotype. The B6;C3-Opa1329-355del mouse is hypothe-
sised to develop visual dysfunction as a result of RGC loss and an
ascending optic neuropathy, whilst the earliest changes detected
in the B6;C3-Opa1Q285STOP mouse are RGC dendritic changes lead-
ing to dysfunctional RGCs. However, it is not clear why the models
should display such a difference in phenotype. The nature of the
mutation and its precise effect on protein tertiary structure may
be relevant. Both mutations give rise to a ca. 50% reduction in pro-
tein levels detected on western blots, suggesting that haploinsufﬁ-
ciency is an element in the pathophysiology. The c.1051C>T
mutation is a nonsense change and truncates the protein immedi-
ately before the GTPase domain (B6;C3-Opa1Q285STOP). It is not
known what, if any, effects the truncated protein fragment may
have on the overall function of the residual protein. The
c.2065+5A>T change is a splice site mutation and gives rise to skip-
ping of exon 10, B6;C3-Opa1329-355del, and a polypeptide with an in-
frame deletion in the GTPase domain. In addition, there are subtle
differences between the two models in terms of genetic back-
ground, the degree of congenicity, as well as breeding and environ-mental factors. In this context it is recognised that there must be
similar effect in patients.
There is evidence for both intra-familial as well as inter-familial
variability in phenotype, and the same mutation in different fami-
lies can result in varying degrees of clinical severity. Genotype/
phenotype correlations in DOA are relatively weak (Yu-Wai-Man
et al., 2010).
Over 200 mutations have so far been reported and some may be
associated with ‘plus’ phenotypes (Yu-Wai-Man et al., 2010). While
the Opa1 models display useful variation in the timing of disease
onset, severity and progression, their data should be considered
separately in view of their different genetic aetiologies. Work still
needs to be done to determine the precise course of disease pro-
gression in the two models and the identiﬁcation of early disease
markers will be essential in order to allow the development of
therapeutic intervention.
The mechanisms directly relating mitochondrial fusion defects
and visual dysfunction remain obscure (Amati-Bonneau et al.,
2009; Heiduschka et al., 2010; Olichon et al., 2006; Williams
et al., 2010; Yarosh, Monserrate, & Tong, 2008). Hypotheses so
far include the role of reactive oxygen species and decreased ATP
levels and lipid peroxidation leading to ATPase dysfunction, as well
as lower rates of Ca2+ sequestering, cytochrome c release and prob-
lems in mitochondrial transport and shuttling. These mechanisms
need to be explored further in detail and their validity as therapeu-
tic targets assessed.
Why are retinal ganglion cells so susceptible to defects in mito-
chondrial function? It may be related to mitochondrial distribution
and mislocalization (Chen & Chan, 2006). Data show the accumu-
lation of mitochondria in varicosities in the soma and unmyeli-
nated, intraretinal axons of RGCs, with a relatively low
population in the post-lamina myelinated axons, perhaps partly
explaining why some areas of the RGC are affected while others
are not (Olichon et al., 2006).
Finally, work is yet to be done on the terminal arbours of the
retinal ganglion cells to see whether these also undergo degenera-
tive changes similar to those seen in dendrites and to determine
the extent to which these changes contribute to the global reduc-
tion in visual sensitivity. The existence of two bona ﬁde mouse
models for DOA provides a ﬁrm foundation for studies into the
pathophysiology of this disease.References
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